• SGLT2 is primarily expressed in human preadipocytes in the epicardial adipose tissue. • The expression levels of SGLT2 diminish as the preadipocytes are differentiated to mature adipocytes. • The SGLT2 inhibitor empagliflozin improves the paracrine secretome profiles, potentially leading to the cardioprotective effect. • IL6 may be a critical adipokine that is regulated by SGLT2 inhibitors.